Cencora acquires OneOncology majority stake for $3.6B, retires $1.3B debt; total cash ~$5.0B

Cencora, Inc.

Enterprise value $7.4B; Cencora paying $3.6B for majority equity and retiring $1.3B OneOncology debt.
Acquisition expected to close by end of fiscal Q2 2026, subject to regulatory approvals.
Cencora paused share repurchases; FY2026 adjusted EPS guidance reiterated but likely lower half of $17.45-$17.75.
Long-term guidance raised: adjusted operating income growth 7-10%, adjusted EPS growth 10-14%.
Financing via new debt; $4.5B bridge financing committed; committed to investment grade ratings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.